Adjuvant Vinorelbine and Cisplatin in Elderly Patients: National Cancer Institute of Canada and Intergroup Study JBR.10
作者： Carmela Pepe , Baktiar Hasan , Timothy L. Winton , Lesley Seymour , Barbara Graham
关键词: Hazard ratio 、 Survival analysis 、 Vinorelbine 、 Performance status 、 Surgery 、 Cancer 、 Medicine 、 Lung cancer 、 Oncology 、 Clinical trial 、 Retrospective cohort study 、 Internal medicine
摘要: Purpose Recent trials have shown significant survival benefit from adjuvant chemotherapy for non–small-cell lung cancer (NSCLC). Whether elderly patients tolerate platinum-based and derive the same advantage is unknown. This retrospective study evaluated influence of age on survival, delivery, toxicity in National Cancer Institute Canada (NCIC) Clinical Trials Group JBR.10. Patients Methods Pretreatment characteristics were compared 327 young (≤ 65 years) 155 (> patients. Chemotherapy delivery 213 treated (63 elderly, 150 young). Results Baseline demographics by similar with exception histology (adenocarcinoma: 58% young, 43% elderly; squamous: 32% 49% P = .001) performance status (PS; PS 0: 53% 41% .01). significantly prolonged overall (hazard ratio, 0.61; ...
elsevier.com
sci-hub.se 参考文章(21)
C. Lequaglie, B. Conti, B. Magnani, P. P. Brega Massone, I. Cataldo, Major surgery in lung cancer in elderly patients? Risk factors analysis and long-term results. Minerva Chirurgica. ,vol. 57, pp. 317- 321 ,(2002)
G. M. Strauss, J. Herndon, M. A. Maddaus, D. W. Johnstone, E. A. Johnson, D. M. Watson, D. J. Sugarbaker, R. L. Schilsky, M. R. Green, Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633 Journal of Clinical Oncology. ,vol. 22, pp. 7019- 7019 ,(2004) , 10.1200/JCO.2004.22.14_SUPPL.7019
L L Siu, F A Shepherd, N Murray, R Feld, J Pater, B Zee, Influence of age on the treatment of limited-stage small-cell lung cancer. Journal of Clinical Oncology. ,vol. 14, pp. 821- 828 ,(1996) , 10.1200/JCO.1996.14.3.821
Clifton F. Mountain, Revisions in the International System for Staging Lung Cancer Chest. ,vol. 111, pp. 1710- 1717 ,(1997) , 10.1378/CHEST.111.6.1710
P. A. Bunn, R. Lilenbaum, Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer Journal of the National Cancer Institute. ,vol. 95, pp. 341- 343 ,(2003) , 10.1093/JNCI/95.5.341
Maurizio Montella, Cesare Gridelli, Anna Crispo, Francesco Scognamiglio, Pasquale Ruffolo, Tindaro Gatani, Vincenzo Boccia, Paolo Maione, Gabriella Fabbrocini, Has lung cancer in the elderly different characteristics at presentation Oncology Reports. ,vol. 9, pp. 1093- 1096 ,(2002) , 10.3892/OR.9.5.1093
Thomas A. Hensing, Amy H. Peterman, Michael J. Schell, Ji-Hyun Lee, Mark A. Socinski, The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer. ,vol. 98, pp. 779- 788 ,(2003) , 10.1002/CNCR.11548
Hidehito Matsuoka, Morihito Okada, Toshihiko Sakamoto, Noriaki Tsubota, Complications and outcomes after pulmonary resection for cancer in patients 80 to 89 years of age. European Journal of Cardio-Thoracic Surgery. ,vol. 28, pp. 380- 383 ,(2005) , 10.1016/J.EJCTS.2005.06.010
Naveed Alam, Frances A. Shepherd, Timothy Winton, Barbara Graham, David Johnson, Robert Livingston, James Rigas, Marlo Whitehead, Keyue Ding, Lesley Seymour, Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer an analysis of National Cancer Institute of Canada and intergroup trial JBR. 10 and a review of the literature Lung Cancer. ,vol. 47, pp. 385- 394 ,(2005) , 10.1016/J.LUNGCAN.2004.08.016
Caio Max S. Rocha Lima, James E. Herndon, Michael Kosty, Gerald Clamon, Mark R. Green, Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer. ,vol. 94, pp. 181- 187 ,(2002) , 10.1002/CNCR.10174